Tim R. Cressey

Researcher Next ID · RN-024538

Researcher · Medicine

University of Liverpool

Liverpool, Thailand

Not currently recruitingFunding unknown

Works count: 221
Citation count: 20,445
H-index: 35
i10-index: 110

Research interests

Medicine

Immunology and Microbiology

HIV/AIDS drug development and treatment

HIV/AIDS Research and Interventions

HIV-related health complications and treatments

HIV Research and Treatment

Pharmaceutical studies and practices

Publications

Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: A global neonatal sepsis observational cohort study (NeoOBS)
PLoS Medicine · 2023 · 10.1371/journal.pmed.1004179
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
The Lancet · 2022 · https://doi.org/10.1016/s0140-6736(21)02724-0
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine · 2021 · 10.1056/nejmoa2108793
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine · 2021 · 10.1056/nejmoa2108793
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
New England Journal of Medicine · 2021 · 10.1056/nejmoa2108793
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings
AIDS · 2019 · 10.1097/qad.0000000000002395
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
Archives of Disease in Childhood · 2019 · 10.1136/archdischild-2019-316816
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 10.1097/qai.0000000000001971
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings
AIDS · 2019 · 10.1097/qad.0000000000002395
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
Archives of Disease in Childhood · 2019 · 10.1136/archdischild-2019-316816
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 10.1097/qai.0000000000001971
Development and validation of the first point-of-care assay to objectively monitor adherence to HIV treatment and prevention in real-time in routine settings
AIDS · 2019 · 10.1097/qad.0000000000002395
Towards understanding global patterns of antimicrobial use and resistance in neonatal sepsis: insights from the NeoAMR network
Archives of Disease in Childhood · 2019 · 10.1136/archdischild-2019-316816
Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 10.1097/qai.0000000000001971
Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B
New England Journal of Medicine · 2018 · 10.1056/nejmoa1708131
Raltegravir Pharmacokinetics During Pregnancy
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 10.1097/qai.0000000000000318
Raltegravir Pharmacokinetics During Pregnancy
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 10.1097/qai.0000000000000318
Raltegravir Pharmacokinetics During Pregnancy
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2014 · 10.1097/qai.0000000000000318
Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2011 · 10.1097/qai.0b013e31823ff052
Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2011 · 10.1097/qai.0b013e31823ff052
Efavirenz Pharmacokinetics During the Third Trimester of Pregnancy and Postpartum
JAIDS Journal of Acquired Immune Deficiency Syndromes · 2011 · 10.1097/qai.0b013e31823ff052
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
PubMed · 2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
PubMed · 2005
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
PubMed · 2005

Current projects

No projects listed.